创伤患者体外生命支持的适应证与结局
该研究为回顾性多机构登记研究,纳入ELSO登记库(1989-2016年)中≥16岁接受ECLS的创伤患者279例,占成人ECLS患者的0.92%。近5年ECLS使用显著增加(2011-2016年173例,62%),以男性为主(78%),平均年龄34.8±15.4岁。胸部损伤最常见,急性呼吸窘迫综合征是最常见适应证;VV-ECLS用于呼吸衰竭占89%,VA用于心衰占7%,VA用于ECLS辅助心肺复苏占4%。ECLS总生存率70%,出院生存率61%(呼吸支持63%、心脏支持50%、E-CPR 25%);超过80%患者发生并发症,最常见为心血管并发症(51%)和出血并发症(29%),多器官衰竭是最常见死因(15.4%)。作者认为创伤不应被视为ECLS的禁忌证,需进一步分析创伤特异性危险因素和ECLS实践以识别最佳候选者并改善结局。
要点
- ELSO登记库1989-2016年279例≥16岁创伤患者接受ECLS,总生存率70%、出院生存率61%。
- 出院生存率因支持类型而异:呼吸支持63%、心脏支持50%、E-CPR 25%。
- VV-ECLS用于呼吸衰竭占89%,VA用于心衰占7%,VA用于E-CPR占4%。
- ECLS期间超过80%患者发生并发症,最常见为心血管并发症(51%)和出血并发症(29%)。
- 多器官衰竭是最常见死因(15.4%);作者认为创伤不应被视为ECLS的禁忌证。
适用人群与场景
- 成人(≥16岁)创伤患者,来自ELSO登记库(1989-2016年)中接受ECLS支持的279例。
- 胸部损伤是最常见诊断,急性呼吸窘迫综合征是最常见适应证。
处置流程与药物剂量
- 呼吸衰竭采用VV-ECLS(占89%),心脏衰竭采用VA-ECLS(占7%),ECLS辅助心肺复苏采用VA-ECLS(E-CPR,占4%)。
- ECLS持续时间平均8.8±9.5天(最长83天),呼吸支持9.3±9.3天,心脏支持4.1±4.5天,E-CPR 6.5±16.8天。
研究设计与关键结果
- 回顾性多机构登记研究:ELSO登记库1989-2016年成人(≥16岁)创伤患者接受ECLS支持279例,占30,273例成人ECLS患者的0.92%。
- ECLS使用近5年显著增加:2011-2016年173例(62%),此前18年106例。
- 人群以男性为主(78%),平均年龄34.8±15.4岁(范围16-88岁)。
- ECLS总生存率70%,出院生存率61%;按支持类型:呼吸支持63%、心脏支持50%、E-CPR 25%。
- 超过80%患者在ECLS期间报告并发症,最常见为心血管并发症(51%),其次为出血并发症(29%)。
- 多器官衰竭是最常见死因(15.4%)。
证据类型、等级与局限
- 证据类型:回顾性多机构登记研究(ELSO登记库),证据等级:治疗性研究,III级。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,随着经验积累和安全性的改善,创伤不应被视为ECLS的禁忌证。
- 作者建议,进一步分析ELSO登记库中创伤特异性危险因素和ECLS特异性实践可能识别最佳候选者并改善创伤ECLS结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: The use of extracorporeal life support (ECLS) in the trauma population remains controversial and has been reported only in small cohort studies. Recent ECLS technical advances have increased its use as an advanced critical care option in trauma. Given the degree of resource utilization, costs, and expertise required to provide ECLS support in trauma patients, we sought to perform a multi-institutional study to assess the indications and outcomes of ECLS in trauma.
METHODS: A retrospective review of adult (≥16 years) trauma patients receiving ECLS support in the Extracorporeal Life Support Organization (ELSO) registry (1989-2016) was performed. Standardized data from the contributing ELSO centers includes patient demographics, diagnoses, and ECLS technique and procedures. Additionally, baseline characteristics, precannulation and postcannulation physiologic data, complications, and outcomes were recorded. Survival was categorized both by transition off ECLS support and survival to hospital discharge.
RESULTS: Two hundred seventy-nine trauma patients were identified (0.92% of 30,273 adult ECLS patients). Extracorporeal life support increased significantly in the last 5 years (173 in 2011-2016, 62%) compared with 106 in the prior 18 years. Trauma patients were predominantly male (78%), with a mean age of 34.8 ± 15.4 years (range, 16-88 years). Thoracic injury was the most common diagnosis; acute respiratory distress syndrome was the most common indication. Extracorporeal life support was venovenous for respiratory failure (89%), VA for cardiac failure (7%), and VA for ECLS-assisted cardiopulmonary resuscitation (CPR) (E-CPR) (4%). Extracorporeal life support duration was 8.8 ± 9.5 days (longest 83 days), and was longer for respiratory support (9.3 ± 9.3 days) vs. cardiac support (4.1 ± 4.5 days) and E-CPR (6.5 ± 16.8 days). Overall survival from ECLS was 70% and survival to hospital discharge was 61% in the total cohort (63% respiratory, 50% cardiac, 25% E-CPR), similar to survival rates in other ELSO registry cohorts. More than 80% of patients had a reported complication during ECLS support. The most common complication was cardiovascular (51%) followed by a bleeding complication (29%). Multiple organ failure was the most common cause of death (15.4%).
CONCLUSION: Data from the largest registry of critically ill trauma patients receiving ECLS support demonstrates reasonable survival. With growing experience and improved safety profile, trauma should not be considered a contraindication for ECLS. Further analysis of the ELSO registry regarding trauma-specific risk factors and ECLS-specific practices may identify best candidates and improve trauma ECLS outcomes.
LEVEL OF EVIDENCE: Therapeutic study, level III.
参考来源
- Swol J, Brodie D, Napolitano L, et al. Indications and outcomes of extracorporeal life support in trauma patients. J Trauma Acute Care Surg. 2018. PMID: 29538235. doi:10.1097/TA.0000000000001895
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。